2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis

Maturitas

Volumn 76, Issue 1, 2013, Pages 99-107

  Mendoza, Nicolás ^a   Sánchez Borrego, Rafael ^b   Villero, José ^c   Baró, Francesc ^d   Calaf, Joaquim ^e   Cancelo, Ma Jesús ^f   Coronado, Pluvio ^g   Estévez, Antonio ^h   Fernández Moya, Jose M ⁱ   González, Silvia ^j   Llaneza, Plácido ^k   Neyro, Jose Luis ^l   Del Pino, Javier ^m   Rodríguez, Esteban ⁿ   Ruiz, Elena ^o   Cano, Antonio ^p  

^a UNIVERSITY OF GRANADA   (Spain)

^b Clinica Diatros   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f UNIVERSITY OF ALCALÁ   (Spain)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^h HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^j Gabinete Medico Velazquez   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL DE CRUCES   (Spain)

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁿ Intelligent Energy Area Telecommunications Technological   (Spain)

^o Centro Médico Sant Feliu   (Spain)

^p HOSPITAL UNIVERSITARIO DR PESET   (Spain)

more..

Author keywords

Bone mineral density; Diagnosis of osteoporosis; Fracture risk assessment; Postmenopausal osteoporosis; Treatment of osteoporosis

Indexed keywords

ALENDRONIC ACID; ANDROGEN; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CATHEPSIN K INHIBITOR; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GESTAGEN; IBANDRONIC ACID; INTEGRIN ANTAGONIST; ISOFLAVONE DERIVATIVE; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROTEIN INHIBITOR; RALOXIFENE; RISEDRONIC ACID; SCLEROSTIN INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TIBOLONE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACNE; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; AMENORRHEA; AMINO ACID BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTERY THROMBOSIS; ARTHRALGIA; ARTHROMYALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ASTHMA; BONE DENSITY; BONE TUMOR; BREAST CANCER; BREAST DISCHARGE; BREAST DISEASE; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CATARACT; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHOLESTATIC HEPATITIS; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; CONSENSUS; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREATINE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEPRESSION; DERMATITIS; DIARRHEA; DIVERTICULITIS; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUODENITIS; DYSGEUSIA; DYSLIPIDEMIA; DYSMENORRHEA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ECZEMA; EDEMA; ENDOMETRIAL DISEASE; ENDOMETRIAL WALL THICKENING; ENDOMETRIUM HYPERPLASIA; EPISCLERITIS; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS EROSION; ESOPHAGUS STENOSIS; ESOPHAGUS ULCER; FAINTNESS; FATIGUE; FEVER; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; FRAGILITY FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENITAL PRURITUS; GLOSSITIS; GLUCOSE INTOLERANCE; GYNECOLOGIST; GYNECOMASTIA; HAIR GROWTH; HEADACHE; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HEART MURMUR; HEART PALPITATION; HEMORRHOID; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOTENSION; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INSOMNIA; IRITIS; JAUNDICE; JAW OSTEONECROSIS; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; LEG CRAMP; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; LIMB PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; LOWER ABDOMINAL PAIN; LUNG EMBOLISM; MASTALGIA; MELENA; MENSTRUATION DISORDER; MIGRAINE; MOOD CHANGE; MOOD DISORDER; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; OTITIS; OVARY CANCER; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PAROSMIA; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; POSTMENOPAUSE BLEEDING; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RASH; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFECTION; RETINA VEIN OCCLUSION; RETINA VEIN THROMBOSIS; RISK ASSESSMENT; RISK REDUCTION; SCIATICA; SEIZURE; SIDE EFFECT; SORE NIPPLE; SPAIN; SWEAT GLAND DISEASE; SWEATING; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; URTICARIA; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; UVEITIS; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA MYCOSIS; VAGINITIS; VASOMOTOR DISORDER; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VIRILIZATION; VOMITING; VULVOVAGINITIS; WEIGHT GAIN; XEROSTOMIA;

EID: 84881192516     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.05.021     Document Type: Article

References (51)

1. M. Naves, J.B. Díaz-López, C. Gómez, A. Rodriguez-Rebollar, and J.B. Cannata-Andia Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50 Osteoporos Int 16 2005 2013 2017
2. F. Baró, A. Cano, and R. Sánchez Borrego Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture Menopause 19 11 2012 1193 1199
3. S. Palacios, C. Christiansen, and R. Sánchez Borrego Recommendations on the management of fragility fracture risk in women younger than 70 years Gynecol Endocrinol 28 2012 770 786
4. http://cebgrade.mcmaster.ca/.
5. J.A. Kanis, E.V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli, J.Y. Reginster Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 24 2013 23 57
6. http://www.qfracture.org.
7. http://www.osteoed.org/tools.php.
8. US Preventive Services Task Force Screening for osteoporosis: recommendation statement Ann Intern Med 154 2011 356 364
9. N. Mendoza, A. Santalla, and F. Morón Características epidemiológicas de una población de mujeres posmenopáusicas con osteopenia y osteoporosis: importancia de la dieta mediterránea Progr Obstet Gynecol 51 2008 265 270
10. M.H. Murad, M.T. Drake, and R.J. Mullan Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis J Clin Endocrinol Metab 97 2012 1871 1880
11. I. Lambrinoudaki, I. Ceasu, and H. Depypere EMAS position statement: diet and health in midlife and beyond Maturitas 74 2013 99 104
12. F.R. Pérez-López, M. Brincat, and C.T. Erel EMAS position statement: vitamin D and postmenopausal health Maturitas 71 2012 83 88
13. T.E. Howe, B. Shea, and L.J. Dawson Exercise for preventing and treating osteoporosis in postmenopausal women Cochrane Database Syst Rev 7 2012 CD000333
14. P.D. Delmas, S.R. Davis, J. Hensen, S. Adami, S. van Os, and E.A. Nijland Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women Osteoporos Int 19 2008 1153 1160
15. J. Marjoribanks, C. Farquhar, H. Roberts, and A. Lethaby Long term hormone therapy for perimenopausal and postmenopausal women Cochrane Database Syst Rev 7 2012 CD004143
16. T.J. de Villiers, M.L. Gass, and C.J. Haines Global consensus statement on menopausal hormone therapy Maturitas 74 2013 391 392
17. B.S. Komm, and A.A. Chines An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis Maturitas 71 2012 221 226
18. S. Palacios, M. Brincat, and C.T. Erel EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis Maturitas 71 2012 194 198
19. P. Collins, L. Mosca, and M.J. Geiger Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors Circulation 119 2009 922 930
20. J.A. Kanis, H. Johansson, A. Oden, and E.V. McCloskey Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 2009 1049 1054
21. S.L. Silverman, A.A. Chines, D.L. Kendler Bazedoxifene Study Group Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos Int 23 2012 351 363
22. T.J. de Villiers, A.A. Chines, and S. Palacios Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial Osteoporos Int 22 2011 567 576
23. G.M. Keating, K.A. Lyseng-Williamson, S.T. Duggan, and K. McKeage Bazedoxifene: a guide to its use in postmenopausal osteoporosis Drugs Aging 29 2012 329 334
24. M. Hiligsmann, W.B. Sedrine, and J.Y. Reginster Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women J Bone Miner Res 28 2013 807 815
25. G.A. Wells, A. Cranney, and J. Peterson Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 2008 CD001155
26. S. Palacios, J.L. Neyro, and J. Ferrer Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate Menopause 19 2012 67 74
27. D.H. Solomon, E. Mercer, S.B. Woo, J. Avorn, S. Schneeweiss, and N. Treister Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges Osteoporos Int 24 2013 237 244
28. C. Mendoza-Edroso, N. Sánchez Garrido-Lestache, and A. Lopez-Picado Postmenopausal osteoporosis: primary prevention or excessive use of medications Semergen 39 2013 123 129
29. E. Chamizo, A. Gallego, E. Loza, A. Herrero, and R. Lozano Systematic literature review of biphosphonates and osteonecrosis of the jaw in patients with osteoporosis Rheumatol Clin 2012 (Epub ahead of print)
30. Food and Drug Administration Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee 2011, September 9
31. http://www.ema.europa.eu/ema/index.
32. N. Freemantle, C. Cooper, and A. Diez-Perez Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Osteoporos Int 24 2013 209 217
33. J.Y. Reginster, J. Badurski, and N. Bellamy Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial Ann Rheum Dis 72 2013 179 186
34. http://www.ema.europa.eu/258269/2013.
35. S. Papapoulos, R. Chapurlat, and C. Libanati Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension J Bone Miner Res 27 2012 694 701
36. J. Goldhahn, J.M. Féron, and J. Kanis Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper Calcif Tissue Int 90 2012 343 353
37. http://www.aemps.es.
38. K. Taku, M.K. Melby, N. Nishi, T. Omori, and M.S. Kurzer Soy isoflavones for osteoporosis: an evidence-based approach Maturitas 70 2011 333 338
39. W. Utian, H. Yu, J. Bobula, S. Mirkin, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women Maturitas 63 2009 329 335
40. J.J. Body, P. Bergmann, and S. Boonen Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications Osteoporos Int 23 2012 S1 S23
41. Martínez-Maestre MÁ, C. González-Cejudo, G. Machuca, R. Torrejón, and C. Castelo-Branco Periodontitis and osteoporosis: a systematic review Climacteric 13 2010 523 529
42. M. Vytrisalova, S. Blazkova, and V. Palicka Self-reported compliance with osteoporosis medication-qualitative aspects and correlates Maturitas 60 2008 223 229
43. S. Epstein, P.D. Delmas, R. Emkey, K.M. Wilson, V. Hiltbrunner, and R.C. Schimmer Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety Maturitas 54 2006 1 10
44. F.R. Pérez-López Postmenopausal osteoporosis and alendronate Maturitas 48 2004 179 192
45. C. Roux, B. Giraudeau, S. Rouanet, G. Dubourg, E. Perrodeau, and P. Ravaud Monitoring of bone turnover markers does not improve persistence with ibandronate treatment Joint Bone Spine 79 2012 389 392
46. V. Breuil, B. Cortet, and F.E. Cotté Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic postmenopausal women Osteoporos Int 23 2012 445 455
47. D.M. Black, I.R. Reid, and S. Boonen The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 27 2012 243 254
48. D.M. Black, A.V. Schwartz, and K.E. Ensrud Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial J Am Med Assoc 296 2006 2927 2938
49. M. Whitaker, J. Guao, T. Kehoe, and G. Benson Bisphosphonates for osteoporosis. Where do we go from here? N Engl J Med 366 2012 2048 2051
50. D.M. Black, D.C. Bauer, A.V. Schwartz, S.R. Cummings, and C.J. Rosen Continuing bisphosphonate treatment for osteoporosis - for whom and for how long? N Engl J Med 366 2012 2051 2053
51. J.A. Cauley, M.E. Danielson, and G.A. Greendale Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation Menopause 19 2012 1200 1207